The US Food and Drug Administration requested immediate removal of ranitidine-containing drugs from the market while also encouraging the industry to make the products more stable because the ingredient remains approved for use in the US.
After testing found levels of the probable carcinogen N-nitrosodimethylamine (NDMA) increases in ranitidine over time in storage, especially at higher temperatures, the FDA for the first time requested withdrawal of an OTC drug that is not defective and otherwise